Furthermore, because a small β-cell population is a major contributor to the progression of DM (34), betagenin’s unique ability to increase the number of β cells, and possibly islets, may represent a significant advantage regarding its potential therapeutic use, because it should preserve or lead to the recovery of insulin production, thereby improving the long-term prognosis of patients. This evidence concerns the gene INS and diabetes mellitus.